Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P17931 (galectin-3)
 2,860 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Angiosarcoma (ASA) in humans and hemangiosarcoma (HSA) in dogs are deadly neoplastic diseases characterized by an aggressive growth of malignant cells with endothelial phenotype, widespread metastasis, and poor response to chemotherapy. Galectin-3 (Gal-3), a beta-galactoside-binding lectin implicated in tumor progression and metastasis, endothelial cell biology and angiogenesis, and regulation of apoptosis and neoplastic cell response to cytotoxic drugs, has not been studied before in tumors arising from malignant endothelia. Here, we tested the hypothesis that Gal-3 could be widely expressed in human ASA and canine HSA and could play an important role in malignant endothelial cell biology. Immunohistochemical analysis demonstrated that 100% of the human ASA (10 of 10) and canine HSA (17 of 17) samples analyzed expressed Gal-3. Two carbohydrate-based Gal-3 inhibitors, modified citrus pectin (MCP) and lactulosyl-l-leucine (LL), caused a dose-dependent reduction of SVR murine ASA cell clonogenic survival through the inhibition of Gal-3 antiapoptotic function. Furthermore, both MCP and LL sensitized SVR cells to the cytotoxic drug doxorubicin to a degree sufficient to reduce the in vitro IC(50) of doxorubicin by 10.7-fold and 3.6-fold, respectively. These results highlight the important role of Gal-3 in the biology of ASA and identify Gal-3 as a potential therapeutic target in tumors arising from malignant endothelial cells.
 ...
PMID:Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. 1778 85

This study aimed to investigate the relationship between the expression of the molecular markers, extracellular matrix metalloproteinase inducer (EMMPRIN), galectin-3, and microvessel density (MVD) with MRI invasive features in invasive and noninvasive pituitary adenomas. MRI was performed preoperatively in 34 patients with histologically verified pituitary adenomas. The expression of EMMPRIN, galectin-3, and MVD was determined by using immunohistochemical techniques on excised surgical specimen from all patients. Correlative analyses between invasive MRI features and expression of EMMPRIN, galectin-3, and MVD were determined between invasive and noninvasive pituitary adenomas. Among MRI invasive features, adenoma crossing the lateral line (LL) of the internal carotid artery (ICA), percentage of intracavernous ICA encasement by the tumor over 50%, sphenoidal sinus invasion, irregular tumor shape, and bilateral ICA asymmetry correlated with increased expression of EMMPRIN and galectin-3 (P<.05), but tumor cystic necrosis and tumor apoplexy did not correlate with EMMPRIN and galectin-3 expression (P>.05). The invasive MRI features did not correlate with MVD expression. This study demonstrated that EMMPRIN and galectin-3 were associated with aggressiveness and invasion by pituitary adenoma. Furthermore, EMMPRIN and galectin-3 were two potential molecular markers for assessing the invasive potential of pituitary adenoma and may provide useful targets for molecular therapeutic strategy against invasive pituitary adenomas.
 ...
PMID:The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. 2151 51